Increased PSMA PET/CT may predict chemotherapy response in metastatic prostate cancer: Study
Belgium: 68Ga-PSMA-11 PET/CT can help predict if patients with metastatic prostate cancer (mPCa) will respond to taxane-based chemotherapy, suggests results from a retrospective analysis. Prostate-specific membrane antigen (PSMA)-expression changes can be used as a predictive biomarker for overall survival (OS) which might be helpful for customizing individual therapy and selecting...
Belgium: 68Ga-PSMA-11 PET/CT can help predict if patients with metastatic prostate cancer (mPCa) will respond to taxane-based chemotherapy, suggests results from a retrospective analysis. Prostate-specific membrane antigen (PSMA)-expression changes can be used as a predictive biomarker for overall survival (OS) which might be helpful for customizing individual therapy and selecting patients eligible for clinical trials. The study was published in the Journal of Nuclear Medicine on November 12, 2021.
Qaid Ahmed Shagera, Department of Nuclear Medicine, Institut Jules Bordet, Universite Libre de Bruxelles (ULB), Belgium, and colleagues aimed to evaluate the role of Positron Emission Tomography (PET) targeting the PSMA for response assessment in mPCa treated with taxane-based chemotherapy (docetaxel or cabazitaxel) and its predictive value on patient outcome.
For this purpose, the researchers retrospectively evaluated 37 patients with metastatic hormone-sensitive or castration-resistant prostate cancer (mHSPC or mCRPC) who underwent t 68Ga-PSMA-11 PET/CT at baseline and after the last cycle of taxane-based chemotherapy (docetaxel or cabazitaxel) without treatment modification between scans.
Biochemical response (BR) was defined as an undetectable or decreased prostate-specific antigen (PSA) by ≥50% compared to baseline. They also tested the association between BR and different PET parameters. A cut-off of ≥30% change in PSMA total tumor volume (PSMA-TV) was used to define PSMA responders (PSMA-R) vs PSMA non-responders (PSMA-NR).
The study cohort was composed of 8 (22%) mHSPC and 29 (78%) mCRPC patients. Twenty-one patients received docetaxel, and 16 received cabazitaxel treatment.
Based on the study, the researchers found the following:
- BR was found in 18/37 patients.
- Using PSMA-TV, PSMA-PET/CT response was concordant with BR in 35/37 patients (Phi=0.89).
- There were 18/37 PSMA-R (6 complete response and 12 partial response) and 19/37 PSMA-NR (17 progressive disease and 2 stable disease).
- After a median follow-up of 23 months there was a statistically significant longer overall survival (OS) for PSMA-R compared to PSMA-NR (median OS not reached vs 12 months, respectively, HR 0.10) for the entire population.
- Among the mCRPC subgroup, differences in OS were also observed (median 22 vs 12 months respectively, HR 0.22) with a 12-month OS rate of 100% for PSMA-R and 52% for PSMA-NR.
"This retrospective analysis suggests that 68Ga-PSMA-11 PET/CT is a promising imaging modality for assessing response to taxane-based chemotherapy in mPCa," wrote the authors. "PSMA-expression changes might be used as a predictive biomarker for OS which might help tailor individual therapy and select eligible patients for clinical trials."
Reference:
68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. Qaid Ahmed Shagera, Carlos Artigas, Ioannis Karfis, Gabriela Critchi, Nieves Martinez Chanza, Spyridon Sideris, Alexandre Peltier, Marianne Paesmans, Thierry Gil, Patrick Flamen. Journal of Nuclear Medicine Nov 2021, jnumed.121.263006; DOI: 10.2967/jnumed.121.263006
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd